Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

Abstract excerpt

The discovery of underlying molecular genetic abnormalities in gastrointestinal stromal tumors (GISTs) such as activating mutations in the tyrosine kinase genes, KIT and platelet derived growth factor receptor-alpha (PDGFRA), has led to remarkable clinical advances in treatment. Small molecule inhibitors such as imatinib and sunitinib are known to inhibit the aberrantly activated KIT and PDGFRA receptor signaling...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal disorders and treatments
• Share to Gastrointestinal Tumor Research and Treatment
• Share to Neurofibromatosis and Schwannoma Cases